**Abstract**

**Objective:** The purposes of this study were to compare the differences between the evidence-based guidelines and real psychiatrists\' prescriptions on patients with major depressive disorder (MDD) and bipolar disorder (BD), and to survey psychiatrist\'s thinking about how to prescribe psychotropic drugs in patients with MDD and BD in general clinical practice.

**Methods:** This study was cross-sectional design. We investigated antipsychotics, antidepressants, mood stabilizers, and benzodiazepines for out-patients with MDD and BD type I and II. We compared real prescriptions to the three latest guidelines, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative guideline, the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines and guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders. We collected clinical data including mood states such as mania/hypomania, depression, or remission at the investigation time, and the questionnaires to assess the reason that psychiatrists prescribed each psychotropic drug to the patients. Among psychotropic

**Results:** We examined 118 patients with MDD and 211 patients with BD (type I, 62; type II, 149) at Chiba University Hospital for June and July 2013. Most of the medications prescribed for BD were those recommended in the guidelines (antidepressants, mood stabilizers, and antipsychotics). Unlike in the guidelines, lamotrigine was prescribed for 17.5% (n = 7/40) bipolar patients with mixed or hypomanic state to expect prevention of future depressive episode and for 13.8% (n = 8/58) patients with MDD to expect antidepressant effect. Low dose of aripiprazole was also prescribed for 10% (n = 8/80) bipolar patients with depressive state to expect improvement of depressive symptoms.

**Conclusion:** This study demonstrated some of psychotropic drugs were prescribed for current symptoms and future expected episodes.
